*Please scroll down to the bottom of the page for the final deliverable.
Crescendo Biologics develops highly differentiated products for cancer therapy using the proprietary Humabody® platform. Humabodies are small, robust protein therapeutics that have fully human VH domains. The origin and size of these Humabodies present distinct advantages over conventional therapeutic antibodies. Crescendo is currently focused on two development programs. These are immuno-oncology modulators and Humabody®-drug conjugates (HDCs).
The objective of this project is to attract the interest of investors, potential partners and potential collaborators. Specifically, video 3 will present Humabody®-drug conjugates (HDCs).
The target audience will have a scientific background and most likely will be working in the Pharmaceutical industry.
With Humabody Drug Conjugates, or HDCs, Crescendo is unlocking the power of antibody drug conjugates.
Carrying just a small amount of highly potent toxin, HDCs are considerably smaller than antibody drug conjugates, or ADCs.
This enables more rapid penetration and accumulation in tumors while also improving clearance from circulation.
Due to their modular structure, multispecific HDC formats have improved specificity for cancer cells by simultaneously binding two or more targets,
and bi- or tri-paratopic formats can dramatically enhance toxin internalization.
This potential for both improved efficacy and reduced toxicity
gives HDCs a superior therapeutic index.
This facilitates a ‘dose high,
hit hard, and leave’ approach,
delivering maximum payload to the tumour
while minimising systemic toxicity.
With HDCs, Crescendo is creating the next generation of drug conjugate therapeutics.